RGS2-deficient mice exhibit decreased intraocular pressure and increased retinal ganglion cell survival

Molecular Vision

Volumn 15, Issue , 2009, Pages 495-504

  Inoue Mochita, Miyuki ^a   Inoue, Toshihiro ^a   Epstein, David L ^a   Blumer, Kendall J ^b   Rao, Ponugoti V ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MYOSIN ADENOSINE TRIPHOSPHATASE; RGS2 PROTEIN;

ACTIN FILAMENT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; AQUEOUS HUMOR; ARTICLE; CELL COUNT; CELL SURVIVAL; CILIARY MUSCLE; CONTROLLED STUDY; HISTOPATHOLOGY; IMMUNOFLUORESCENCE TEST; INTRAOCULAR PRESSURE; MALE; MOUSE; MUSCLE CONTRACTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RETINA GANGLION CELL; SCHLEMM CANAL; TONOMETER; TRABECULAR MESHWORK; WILD TYPE;

ANIMALS; AQUEOUS HUMOR; BASE SEQUENCE; CELL SURVIVAL; CILIARY BODY; CORNEA; DNA PRIMERS; INTRAOCULAR PRESSURE; IRIS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MUSCLE CONTRACTION; RETINAL GANGLION CELLS; RGS PROTEINS;

EID: 62849127970     PISSN: None     EISSN: 10900535     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. Weinreb RN, Khaw PT. Primary open-angle glaucoma. Lancet 2004; 363:1711-20.
2. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol 2006; 90:262-7.
3. Woodward DF, Gil DW. The inflow and outflow of antiglaucoma drugs. Trends Pharmacol Sci 2004; 25:238-41.
4. Gabelt BT, Kaufman PL. Changes in aqueous humor dynamics with age and glaucoma. Prog Retin Eye Res 2005; 24:612-37.
5. Lutjen-Drecoll E. Functional morphology of the trabecular meshwork in primate eyes. Prog Retin Eye Res 1999; 18:91-119.
6. Wiederholt M, Thieme H, Stumpff F. The regulation of trabecular meshwork and ciliary muscle contractility. Prog Retin Eye Res 2000; 19:271-95.
7. Rao VP, Epstein DL. Rho GTPase/Rho kinase inhibition as a novel target for the treatment of glaucoma. BioDrugs 2007; 21:167-77.
8. Honjo M, Tanihara H, Inatani M, Kido N, Sawamura T, Yue BY, Narumiya S, Honda Y. Effects of rho-associated protein kinase inhibitor Y-27632 on intraocular pressure and outflow facility. Invest Ophthalmol Vis Sci 2001; 42:137-44.
9. Uehata M, Ishizaki T, Satoh H, Ono T, Kawahara T, Morishita T, Tamakawa H, Yamagami K, Inui J, Maekawa M, Narumiya S. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature 1997; 389:990-4.
10. Rao PV, Deng P, Sasaki Y, Epstein DL. Regulation of myosin light chain phosphorylation in the trabecular meshwork: role in aqueous humour outflow facility. Exp Eye Res 2005; 80:197-206.
11. Mettu PS, Deng PF, Misra UK, Gawdi G, Epstein DL, Rao PV. Role of lysophospholipid growth factors in the modulation of aqueous humor outflow facility. Invest Ophthalmol Vis Sci 2004; 45:2263-71.
12. Tang KM, Wang GR, Lu P, Karas RH, Aronovitz M, Heximer SP, Kaltenbronn KM, Blumer KJ, Siderovski DP, Zhu Y, Mendelsohn ME. Regulator of G-protein signaling-2 mediates vascular smooth muscle relaxation and blood pressure. Nat Med 2003; 9:1506-12.
13. Heximer SP, Knutsen RH, Sun X, Kaltenbronn KM, Rhee MH, Peng N, Oliveira-dos-Santos A, Penninger JM, Muslin AJ, Steinberg TH, Wyss JM, Mecham RP, Blumer KJ. Hypertension and prolonged vasoconstrictor signaling in RGS2-deficient mice. J Clin Invest 2003; 111:445-52.
14. Osei-Owusu P, Sun X, Drenan RM, Steinberg TH, Blumer KJ. Regulation of RGS2 and second messenger signaling in vascular smooth muscle cells by cGMP-dependent protein kinase. J Biol Chem 2007; 282:31656-65.
15. Sun X, Kaltenbronn KM, Steinberg TH, Blumer KJ. RGS2 is a mediator of nitric oxide action on blood pressure and vasoconstrictor signaling. Mol Pharmacol 2005; 67:631-9.
16. Heximer SP, Blumer KJ. RGS proteins: Swiss army knives in seven-transmembrane domain receptor signaling networks. Sci STKE 2007; 2007:pe2.
17. Hollinger S, Hepler JR. Cellular regulation of RGS proteins: modulators and integrators of G protein signaling. Pharmacol Rev 2002; 54:527-59.
18. Heximer SP, Watson N, Linder ME, Blumer KJ, Hepler JR. RGS2/G0S8 is a selective inhibitor of Gqalpha function. Proc Natl Acad Sci USA 1997; 94:14389-93.
19. Wettschureck N, Rütten H, Zywietz A, Gehring D, Wilkie TM, Chen J, Chien KR, Offermanns S. Absence of pressure overload induced myocardial hypertrophy after conditional inactivation of Galphaq/Galpha11 in cardiomyocytes. Nat Med 2001; 7:1236-40.
20. Feuerstein GZ, Rozanski D. G proteins and heart failure: is Galphaq a novel target for heart failure? Circ Res 2000; 87:1085-6.
21. Wettschureck N, Offermanns S. Mammalian G proteins and their cell type specific functions. Physiol Rev 2005; 85:1159-204.
22. Somlyo AP, Somlyo AV. Ca2+ sensitivity of smooth muscle and nonmuscle myosin II: modulated by G proteins, kinases, and myosin phosphatase. Physiol Rev 2003; 83:1325-58.
23. Wang WH, Millar JC, Pang IH, Wax MB, Clark AF. Noninvasive measurement of rodent intraocular pressure with a rebound tonometer. Invest Ophthalmol Vis Sci 2005; 46:4617-21.
24. Song J, Deng PF, Stinnett SS, Epstein DL, Rao PV. Effects of cholesterol-lowering statins on the aqueous humor outflow pathway. Invest Ophthalmol Vis Sci 2005; 46:2424-32.
25. Urcola JH, Hernandez M, Vecino E. Three experimental glaucoma models in rats: comparison of the effects of intraocular pressure elevation on retinal ganglion cell size and death. Exp Eye Res 2006; 83:429-37.
26. Ji J, Chang P, Pennesi ME, Yang Z, Zhang J, Li D, Wu SM, Gross RL. Effects of elevated intraocular pressure on mouse retinal ganglion cells. Vision Res 2005; 45:169-79.
27. Gan L, Wang SW, Huang Z, Klein WH. POU domain factor Brn-3b is essential for retinal ganglion cell differentiation and survival but not for initial cell fate specification. Dev Biol 1999; 210:469-80.
28. Wiederholt M, Schafer R, Wagner U, Lepple-Wienhues A. Contractile response of the isolated trabecular meshwork and ciliary muscle to cholinergic and adrenergic agents. Ger J Ophthalmol 1996; 5:146-53.
29. Marquis RE, Whitson JT. Management of glaucoma: focus on pharmacological therapy. Drugs Aging 2005; 22:1-21.
30. Erickson KA, Schroeder A. Direct effects of muscarinic agents on the outflow pathways in human eyes. Invest Ophthalmol Vis Sci 2000; 41:1743-8.
31. Pang IH, Clark AF. Rodent models for glaucoma retinopathy and optic neuropathy. J Glaucoma 2007; 16:483-505.
32. Savinova OV, Sugiyama F, Martin JE, Tomarev SI, Paigen BJ, Smith RS, John SW. Intraocular pressure in genetically distinct mice: an update and strain survey. BMC Genet 2001; 2:12.
33. Zhou Y, Grinchuk O, Tomarev SI. Transgenic mice expressing the Tyr437His mutant of human myocilin protein develop glaucoma. Invest Ophthalmol Vis Sci 2008; 49:1932-9.
34. Li R, Liu JH. Telemetric monitoring of 24 h intraocular pressure in conscious and freely moving C57BL/6J and CBA/CaJ mice. Mol Vis 2008; 14:745-9.
35. Grierson I, Lee WR, Abraham S. Effects of pilocarpine on the morphology of the human outflow apparatus. Br J Ophthalmol 1978; 62:302-13.
36. Lutjen-Drecoll E, Wiendl H, Kaufman PL. Acute and chronic structural effects of pilocarpine on monkey outflow tissues. Trans Am Ophthalmol Soc 1998; 96:171-91.
37. Rohen JW, Lutjen E, Barany E. The relation between the ciliary muscle and the trabecular meshwork and its importance for the effect of miotics on aqueous outflow resistance. A study in two contrasting monkey species, Macaca irus and Cercopithecus aethiops. Albrecht Von Graefes Arch Klin Exp Ophthalmol 1967; 172:23-47.
38. Gupta N, Drance SM, McAllister R, Prasad S, Rootman J, Cynader MS. Localization of M3 muscarinic receptor subtype and mRNA in the human eye. Ophthalmic Res 1994; 26:207-13.
39. Shade DL, Clark AF, Pang IH. Effects of muscarinic agents on cultured human trabecular meshwork cells. Exp Eye Res 1996; 62:201-10.
40. Gabelt BT, Kaufman PL, Polansky JR. Ciliary muscle muscarinic binding sites, choline acetyltransferase, and acetylcholinesterase in aging rhesus monkeys. Invest Ophthalmol Vis Sci 1990; 31:2431-6.
41. Wettschureck N, Offermanns S. Rho/Rho-kinase mediated signaling in physiology and pathophysiology. J Mol Med 2002; 80:629-38.
42. Obst M, Tank J, Plehm R, Blumer KJ, Diedrich A, Jordan J, Luft FC, Gross V. NO-dependent blood pressure regulation in RGS2-deficient mice. Am J Physiol Regul Integr Comp Physiol 2006; 290:R1012-9.
43. Kamikawatoko S, Tokoro T, Ishida A, Masuda H, Hamasaki H, Sato J, Azuma H. Nitric oxide relaxes bovine ciliary muscle contracted by carbachol through elevation of cyclic GMP. Exp Eye Res 1998; 66:1-7.
44. Nathanson JA, McKee M. Identification of an extensive system of nitric oxide-producing cells in the ciliary muscle and outflow pathway of the human eye. Invest Ophthalmol Vis Sci 1995; 36:1765-73.
45. Doggrell SA. Is RGS-2 a new drug development target in cardiovascular disease? Expert Opin Ther Targets 2004; 8:355-8.
46. Morris CA, Crowston JG, Lindsey JD, Danias J, Weinreb RN. Comparison of invasive and non-invasive tonometry in the mouse. Exp Eye Res 2006; 82:1094-9.
47. Johnson TV, Fan S, Toris CB. Rebound tonometry in conscious, conditioned mice avoids the acute and profound effects of anesthesia on intraocular pressure. J Ocul Pharmacol Ther 2008; 24:175-85.
48. Fatemi SH, Reutiman TJ, Folsom TD, Bell C, Nos L, Fried P, Pearce DA, Singh S, Siderovski DP, Willard FS, Fukuda M. Chronic olanzapine treatment causes differential expression of genes in frontal cortex of rats as revealed by DNA microarray technique. Neuropsychopharmacology 2006; 31:1888-99.
49. Geurts M, Maloteaux JM, Hermans E. Altered expression of regulators of G-protein signaling (RGS) mRNAs in the striatum of rats undergoing dopamine depletion. Biochem Pharmacol 2003; 66:1163-70.
50. Kobori N, Clifton GL, Dash P. Altered expression of novel genes in the cerebral cortex following experimental brain injury. Brain Res Mol Brain Res 2002; 104:148-58.
51. Homme M, Schmitt CP, Himmele R, Hoffmann GF, Mehls O, Schaefer F. Vitamin D and dexamethasone inversely regulate parathyroid hormone-induced regulator of G protein signaling-2 expression in osteoblast-like cells. Endocrinology 2003; 144:2496-504.
52. Ruiz-Ederra J, Verkman AS. Mouse model of sustained elevation in intraocular pressure produced by episcleral vein occlusion. Exp Eye Res 2006; 82:879-84.
53. Levkovitch-Verbin H, Harizman N, Dardik R, Nisgav Y, Vander S, Melamed S. Regulation of cell death and survival pathways in experimental glaucoma. Exp Eye Res 2007; 85:250-8.
54. Huang W, Fileta JB, Dobberfuhl A, Filippopolous T, Guo Y, Kwon G, Grosskreutz CL. Calcineurin cleavage is triggered by elevated intraocular pressure, and calcineurin inhibition blocks retinal ganglion cell death in experimental glaucoma. Proc Natl Acad Sci USA 2005; 102:12242-7.
55. Neufeld AH, Gachie EN. The inherent, age-dependent loss of retinal ganglion cells is related to the lifespan of the species. Neurobiol Aging 2003; 24:167-72.
56. Ida H, Boylan SA, Weigel AL, Hjelmeland LM. Age-related changes in the transcriptional profile of mouse RPE/choroid. Physiol Genomics 2003; 15:258-62.
57. Wolf N, Penn P, Pendergrass W, Van Remmen H, Bartke A, Rabinovitch P, Martin GM. Age-related cataract progression in five mouse models for anti-oxidant protection or hormonal influence. Exp Eye Res 2005; 81:276-85.
58. The Advanced Glaucoma Intervention Study (AGIS). 7. The relationship between control of intraocular pressure and visual field deterioration.The AGIS Investigators. Am J Ophthalmol 2000; 130:429-40.
59. Pereira SP, Medina SV, Araujo EG. Cholinergic activity modulates the survival of retinal ganglion cells in culture: the role of M1 muscarinic receptors. Int J Dev Neurosci 2001; 19:559-67.